References
- Björntorp P. Body fat distribution, insulin resistance and metabolic diseases. Nutrition 13, 795–803 (1997).
- Björntorp P. Regional fat distribution – implications for Type II diabetes. Int. J. Obes. Relat. Metab. Disord. 16(Suppl. 4), S19–S27 (1992).
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 352, 837–853 (1998).
- Yki-Järvinen H. Thiazolidinediones. N. Engl. J. Med. 351, 1106–1118 (2004).
- Ruan H, Lodish HF. Regulation of insulin sensitivity by adipose tissue-derived hormones and inflammatory cytokines. Curr. Opin. Lipidol. 15, 297–302 (2004).
- Mayer-Davis EJ, Costacou T. Obesity and sedentary lifestyle: modifiable risk factors for prevention of Type 2 diabetes. Curr. Diab. Rep. 1, 170–176 (2001).
- Lindström J, Louheranta A, Mannelin M et al., the Finnish Diabetes Prevention Study Group. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 26, 3230–3236 (2003).
- Knowler WC, Barrett-Connor E, Fowler SE et al., the Diabetes Prevention Program Research Group. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002).
- Holt R. Orlistat reduces features of the metabolic syndrome: the XENDOS study. Diabetes Obes. Metab. 5, 356 (2003).
- Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, the STOP-NIDDM Trial Research Group. Acarbose for prevention of Type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 359, 2072–2077 (2002).
- Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of Type 2 diabetes in obese patients. Diabetes Care 27, 155–161 (2004).
- Lean ME, Powrie JK, Anderson AS, Garthwaite PH. Obesity, weight loss and prognosis in Type 2 diabetes. Diabet. Med. 7, 228–233 (1990).
- Mayer-Davis EJ, D’Antonio AM, Smith SM et al. Pounds Off With EmpoweRment (POWER): a clinical trial of weight management strategies for Black and White adults with diabetes who live in medically underserved rural communities. Am. J. Public Health 94, 1736–1742 (2004).
- Ryan DH, Espeland MA, Foster GD et al., the Look AHEAD Research Group. Look AHEAD (Action for HEAlth in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in Type 2 diabetes. Control Clin. Trials 24, 610–628 (2003).
- Sjöström CD, Peltonen M, Wedel H, Sjöström L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 36, 20–25 (2000).
- Torgerson JS, Sjöström L. The Swedish Obese Subjects (SOS) study – rationale and results. Int. J. Obes. Relat. Metab. Disord. 25(Suppl. 1), S2–S4 (2001).
- Sjöström L, Lindroos AK, Peltonen M et al., the Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351, 2683–2693 (2004).
- Wing RR, Venditti E, Jakicic JM, Polley BA, Lang W. Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care 21, 350–359 (1998).
- Williams KV, Mullen ML, Kelley DE, Wing RR. The effect of short periods of caloric restriction on weight loss and glycemic control in Type 2 diabetes. Diabetes Care 21, 2–8 (1998).
- Tate DF, Jackvony EH, Wing RR. Effects of internet behavioral counseling on weight loss in adults at risk for Type 2 diabetes: a randomized trial. J. Am. Med. Assoc. 289, 1833–1836 (2003).
- Pories WJ, Swanson MS, MacDonald KG et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann. Surg. 222, 339–350 (1995).